Loss of FBP1 facilitates aggressive features of hepatocellular carcinoma cells through the Warburg effect

Carcinogenesis. 2017 Feb 1;38(2):134-143. doi: 10.1093/carcin/bgw109.

Abstract

Reprogrammed metabolism has been identified as an emerging hallmark in cancer cells. It has been demonstrated that fructose-1, 6-bisphosphatase 1 (FBP1) as a rate-limiting enzyme in gluconeogenesis plays critical roles in tumor initiation and progression in several cancer types. However, function of FBP1 in hepatocellular carcinoma (HCC) is still not clear. In this study, we observed that the expression of FBP1 was obviously downregulated in the cell lines and tissues of HCC. Downregulation of FBP1 in HCC tissues was correlated with a lower overall survival rate and had a relatively higher tendency of tumor recurrence (n = 224). Silencing FBP1 could significantly promote colony formation, proliferation and metastasis of HCC cells, while ectopic overexpression of FBP1 resulted in impaired abilities of colony formation, proliferation and metastasis in vitro and in vivo. Mechanistically, silencing FBP1 facilitated glycolysis in HCC cell lines, which may be responsible for aggressiveness of HCC cells. We further found that targeting the Warburg effect using the specific inhibitor FX11 could suppress the aggressiveness of HCC cells which was mediated by loss of FBP1. These findings indicate that FBP1 appears to be a tumor suppressor in HCC. Strategies to restore the levels and activities of FBP1 might be developed to treat patients with HCC.

MeSH terms

  • Animals
  • Carcinoma, Hepatocellular / drug therapy
  • Carcinoma, Hepatocellular / genetics*
  • Carcinoma, Hepatocellular / pathology
  • Cell Proliferation / genetics
  • Cell Transformation, Neoplastic / genetics*
  • DNA Helicases / antagonists & inhibitors
  • DNA Helicases / genetics*
  • DNA-Binding Proteins / antagonists & inhibitors
  • DNA-Binding Proteins / genetics*
  • Disease Progression
  • Gene Expression Regulation, Neoplastic
  • Gene Silencing
  • Gluconeogenesis / drug effects
  • Gluconeogenesis / genetics
  • Hep G2 Cells
  • Humans
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / genetics*
  • Liver Neoplasms / pathology
  • Mice
  • Naphthalenes / administration & dosage
  • Neoplasm Metastasis
  • RNA-Binding Proteins
  • Xenograft Model Antitumor Assays

Substances

  • 3-dihydroxy-6-methyl-7-(phenylmethyl)-4-propylnaphthalene-1-carboxylic acid
  • DNA-Binding Proteins
  • FUBP1 protein, human
  • Naphthalenes
  • RNA-Binding Proteins
  • DNA Helicases